Moxifloxacin Olikla (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Olikla, is a fluoroquinolone antibiotic presented as an intravenous formulation for intravenous use. It is employed to treat a variety of serious bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and complicated intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacin Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides quality‑assured batches to healthcare institutions, ensuring regulatory compliance and reliable cold‑chain logistics where required.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in the respiratory, sinus, skin, and intra‑abdominal systems. - Community‑acquired bacterial pneumonia: reduces bacterial load and improves clinical outcomes in adult patients. - Acute bacterial sinusitis: eradicates causative pathogens and alleviates sinus inflammation. - Acute bacterial exacerbation of chronic bronchitis: controls infection and helps restore lung function. - Skin and skin structure infections: eliminates susceptible Gram‑negative and Gram‑positive organisms. - Complicated intra‑abdominal infections: provides broad‑spectrum coverage against mixed aerobic and anaerobic bacteria.

Moxifloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: cardiac arrhythmia risk, monitor ECG. - Severe hypersensitivity: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.

When prescribing moxifloxacin, clinicians should consider several safety and handling precautions. - Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or concurrent QT‑prolonging drugs. - Tendon disorders: advise patients to report tendon pain, especially if elderly or on corticosteroids. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and do not freeze.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increase risk of QT prolongation. - Class Ia and III antiarrhythmics (e.g., quinidine, amiodarone): may cause serious cardiac events. - Theophylline: increased serum levels leading to toxicity. - Warfarin: enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduced effectiveness; advise backup contraception. - Corticosteroids: heightened risk of tendon rupture. - Cyclosporine: may increase moxifloxacin concentrations. - NSAIDs: potential additive gastrointestinal irritation. - Diabetic agents (e.g., insulin, sulfonylureas): monitor blood glucose as hypoglycemia may occur.